Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Morschhauser, Franck; Fowler, Nathan H; Feugier, Pierre; Bouabdallah, Reda; Tilly, Hervé; Palomba, M Lia; Fruchart, Christophe; Libby, Edward N; Casasnovas, Rene-Olivier; Flinn, Ian W; Haioun, Corinne; Maisonneuve, Hervé; Ysebaert, Loic; Bartlett, Nancy L; Bouabdallah, Kamal; Brice, Pauline; Ribrag, Vincent; Daguindau, Nicolas; Le Gouill, Steven; Pica, Gian M; Martin Garcia-Sancho, Alejandro; López-Guillermo, Armando; Larouche, Jean-François; Ando, Kiyoshi; Gomes da Silva, Maria; André, Marc; Zachée, Pierre; Sehn, Laurie H; Tobinai, Kensei; Cartron, Guillaume; Liu, David; Wang, Jianming; Xerri, Luc; Salles, Gilles A; Abdel-Samad, N; Abdo-Matkiwsky, M; Abraham, J; Abrisqueta, P; Anglaret, B; Barnes, Ja; Benbrahim, O; Bierman, Pj; Bonnet, C; Brault, P; Bron, D; Brooks BJ Jr,; Byeff, P; Casanova, M; Cheung, M; Choudhary, Y; Comeau, T; Cooper, B; Couban, S; Cox, Mc; Crump, M; Deau Fischer, B; Deconinck, E; Deeren, D; de la Cruz Vicente, F; Delarue, R; Del Campo, R; Delmer, A; Delwail, V; Duggan, Pr; Djrm, Eisenmann; El Yamani, A; Eradat, Ha; Fabbro, M; Farber, C; Fisher, Dc; Fleischman, Ra; Fleck, E; Fornecker, Lm; Foussard, C; Gabarre, J; Gaffar, Ya; Gallardo, D; Ghazal, H; Giagounidis, A; Gill, K; Glaisner, S; Gonzalez, H; Greenberg, Rh; Goubran Messiha, H; Goy, A; Gressin, R; Gyan, E; Hart, Ll; Hatake, K; Hiddemann, W; Hodossy, B; Horkheimer, I; Hoyer, Rj; Huebel, K; Ishikawa, T; Izutsu, K; Jardel, H; Jhangiani, Hs; Johnson, N; Joly, B; Jourdan, E; Kargar Samani, K; Kato, K; Kiguchi, T; Kobayashi, T; Kohser, F; Koike, M; C T, Kouroukis; Laferriere, N; Lamy de la Chapelle, T; Landau, Da; Lawler, We; Lemieux, B; Levitan, Da; Longree, L; Lopez, J; Mace, J; Maerevoet, M; Maigre, M; Marjanovic, Z; Michel, J; Mounier, C; Muntanola, A; Ngirabacu, Mc; Nicolas-Virelizier, E; Novelli, S; Offner, F; Palomera, L; Pandit, Lh; Panwalkar, A; Pierre, P; Pignon, Jm; Pinto, A; Plöger, C; Pranger, D; Quick, Dp; Reyes, Ea; Robin, V; Robu, D; Rodriguez Salazar MJ,; Rosen, Pj; Rosenbluth, J; Sadot-Lebouvier, S; Sangha, R; Segota, Z; Shapira, I; Shtivelband, M; Simon, M; Soekler, M; Soubeyran, P; Taper, J; Tereblo, Hr; Terol, Mj; The, As; Ueda, Y; van den Neste, E; van Eygen, K; van Hoof, A; Vanstraelen, G; Verner, E; Warburton, P; Yamamoto, G; Yokoyama, H; Zerazhi, H; Zinzani, Pl.

doi:10.1056/NEJMoa1805104

Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma.

Morschhauser, F., Fowler, N.H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M.L., et al. (2018). Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. THE NEW ENGLAND JOURNAL OF MEDICINE, 379(10), 934-947 [10.1056/NEJMoa1805104].